Evidence map›Paper›PMID 40823854›Full record

ArticleDermatology reports2026

A bibliometric study of the top 100 most-cited articles on melanoma: insights into research trends and characteristics.

Jinhao Zhang, Xiangze Meng, Yun Wang, Wei Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Comment on "Artificial Intelligence in melanoma research: a bibliometric analysis".International journal of surgery (London, England) · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jinhao ZhangDepartment of Oral and Maxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai; College of Stomatology, Shanghai Jiao Tong University, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai.
Xiangze MengDepartment of Oral and Maxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai; College of Stomatology, Shanghai Jiao Tong University, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai.
Yun WangDepartment of Dermatology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai.
Wei LiuDepartment of Oral and Maxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai; College of Stomatology, Shanghai Jiao Tong University, National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology, Shanghai.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Improving insights into current research and literature on melanoma enables healthcare providers to offer patients better care by applying the latest advancements. This bibliometric study analyzed the characteristics and trends in melanoma research through the top-cited articles. The top 100 most-cited articles on melanoma were published between 1969 and 2020, and the average number of citations was 36.8-893.9 (mean 176.8). Notably, the frequencies of the main key words, including antineoplastic agents, genetics, randomized controlled trials, metastatic melanoma, BRAF, and monoclonal antibodies, during 2010-2020 were significantly higher than during 1969-2009. Specifically, the main study topics after 2010 were drug research aspects, such as drug safety, drug efficacy, drug resistance, drug withdrawal, cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death 1/programmed death-ligand 1 (PD-1/PD-L1), ipilimumab, nivolumab, trametinib, dabrafenib, vemurafenib, and various drug adverse effects. The emergence of immunotherapy caused a burst of citations and substantially changed the distribution of top-cited articles.

Indexed as

Bibliometricsimmune checkpoint inhibitorsimmunotherapymelanomaresearch characteristics

Identifiers

PMID40823854
PMCPMC13281541

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.